GW-876167
GW-876167 had been in phase II clinical trials for the treatment of obesity and glaucoma; however, no recent development has been reported for this indication.
The compound is developed by Upsher-Smith.
General Information
Update Date：2016-03-29
- Drug Name：
- GW-876167
- Research Code：
- GW-876167; BVT-933; PNU-183933; PRX-00933
- Trade Name：
- MOA：
- 5-HT2C agonist
- Indication：
- Obesity; Glaucoma
- Status：
- Phase Ⅱ (Pending)
- Company：
- Upsher Smith Laboratories (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-10-19
|
Molecular Weight | 315.37 | ||||||||||||
| Formula | C16H21N5O2 | |||||||||||||
| CAS No. | 313658-33-2 (PRX 933); | |||||||||||||
| Chemical Name | Pyrazine, 2-[(2R)-2-methyl-1-piperazinyl]-3-[2-(3-pyridinyloxy)ethoxy]- | |||||||||||||
| PRX 933 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||